India's drug regulator has granted restricted emergency use authorisation to the Serum Institute's COVID-19 vaccine Covovax for the 12-17 age-group subject to certain conditions.
Confirming the Drugs Controller General of India's (DCGI) approval, Serum Institute of India Chief Executive Officer Adar Poonawalla on Tuesday tweeted: "@SerumInstIndia's brand Covovax has completed bridging studies in India and has been granted Emergency Use Authorisation by DCGI for adults and for children above the age of 12. Younger age groups will follow shortly."
It is the fourth vaccine to receive the regulator's nod for use among those below 18 years. However, only one vaccine — Bharat Biotech's Covaxin — is used for the 15-18 age-group in the vaccination drive in the country after the government approval.
